Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Molecular & Cellular Proteomics · 2023
DOI: 10.1016/j.mcpro.2023.100517 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular & Cellular Proteomics, 2023. Verfasst von Pedro Casado und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cell Signalling & Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, U…. Hauptthemen laut MEDLINE: Precision Medicine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK, Barts Charity, Blood Cancer UK.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a highly heterogeneous cancer of the hematopoietic system with no cure for most patients. In addition to chemotherapy, treatment options for AML include recently approved therapies that target proteins with roles in AML pathobiology, such as FLT3, BLC2, and IDH1/2. However, due to disease complexity, these therapies produce very diverse responses, and survival rates are still low. Thus, despite considerable advances, there remains a need for therapies that target different aspects of leukemic biology and for associated biomarkers that define patient populations likely to respond to each available therapy. To meet this need, drugs that target different AML vulnerabilities are currently in advanced stages of clinical development. Here, we review proteomics and phosphoproteomics studies that aimed to provide insights into AML biology and clinical disease heterogeneity not attainable with genomic approaches. To place the discussion in context, we first provide an overview of genetic and clinical aspects of the disease, followed by a summary of proteins targeted by compounds that have been approved or are under clinical trials for AML treatment and, if available, the biomarkers that predict responses. We then discuss proteomics and phosphoproteomics studies that provided insights into AML pathogenesis, from which potential biomarkers and drug targets were identified, and studies that aimed to rationalize the use of synergistic drug combinations. When considered as a whole, the evidence summarized here suggests that proteomics and phosphoproteomics approaches can play a crucial role in the development and implementation of precision medicine for AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cell Signalling & Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
- Cell Signalling & Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; The Alan Turing Institute, The British Library, London,…
Förderung
- Cancer Research UK
- Barts Charity
- Blood Cancer UK
Zitieren
APA
Casado, P., & Cutillas, P. R. (2023). Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2023.100517
Vancouver
Casado P, Cutillas PR. Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine. Molecular & Cellular Proteomics. 2023. doi:10.1016/j.mcpro.2023.100517
BibTeX
@article{Casado2023,
author = {Casado, Pedro and Cutillas, Pedro R},
title = {Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine},
journal = {Molecular & Cellular Proteomics},
year = {2023},
doi = {10.1016/j.mcpro.2023.100517}
}
EUVIMED